Jun 26, 2017, 4:55 PM ETConference Presentation, Panel, Fireside Chat

Medical Marijuana: Health and (Financial) Wellness

The legal medical and recreational cannabis market is projected to reach $40–$45 billion in estimated demand, positioning it just below the beer market and above the wine market.
Current legal market revenue is approximately $4 billion, representing a fraction of a potential $70 billion total market (including the illegal sector) that is undergoing a conversion process.
28 U.S. states currently have legal medical programs, and 70% of U.S. states are projected to be legal medically by the end of the panel's timeframe.
Global legalization trends are accelerating, with Germany, Argentina, Brazil, and Mexico recently legalizing medical consumption, creating a potential $12 billion export market within three months.
In Canada, estimated demand is 500 tons annually, while current total production capacity is less than 40 tons, indicating significant supply shortages.
Polling data indicates 70–90% of Americans favor medical marijuana legalization, with recreational legalization support trending above 60%.
In Illinois, states with legal medical programs report a 25% reduction in opiate-related deaths compared to non-legal states.
Colorado generated approximately $1.2 billion in tax revenue from cannabis last year, demonstrating significant fiscal potential for other states.

Green Thumb Industries (Ben Kovler): Operates 11 licenses across Illinois, Nevada, Massachusetts, Maryland, and New Jersey for cultivation, processing, and distribution; reports 100% compliance with state banking regulations.
Mary's Medicinals (Lynn Hondred): Launched the first transdermal cannabis patch; operates in 8 states (expanding to 12) with 10 product lines and over 32 SKUs; emphasizes the "medical" angle to reduce stigma.
Union Group / International Cannabis Corporation (Juan Sartori): Focuses on low-cost production and export from Uruguay, leveraging favorable climate conditions to produce at roughly 1/10th the cost of Canadian operations.
Chatham Capital (Brian Reynolds): Focuses on early-stage equity investments, including facilities in Rhode Island, Colorado, Malibu, and partnerships with the Cabazon Indian Tribe.
Vertical Integration: Successful operators argue that controlling the full supply chain—from cultivation to retail—is critical for maintaining margins and withstanding price reductions.
Unit Economics: Production costs are estimated at $500–$700 per pound, while retail prices average $5,000 per pound, indicating significant margin potential for vertically integrated companies.
Brand Strategy: Panelists identify the future market as a "brand game" where established consumer brands (e.g., "Marlboro of cannabis") will dominate over the long term, rather than pure commodity growers.

Federal Banking Constraints: Despite state legality, cannabis companies remain federally illegal (Class I controlled substance), preventing access to traditional federal banking; operations rely on state-chartered banks or credit unions.
Financial Compliance: Companies face rigorous compliance requirements, including FinCEN guidelines and the Cole Memo, to maintain bank accounts; many traditional banks (e.g., Chase, BoA) refuse to serve the industry.
Payroll Risks: Even with state licenses, payroll services occasionally shut down business accounts, forcing companies to process cash payrolls, creating security risks and operational friction.
IRS Code 280E: Cannabis businesses are subject to IRS Code 280E, which prohibits standard tax deductions (including marketing and rent), significantly reducing net profitability despite high gross margins.
Regulatory Moat: Panelists view federal illegality as a temporary "moat" that limits institutional investment, creating a window for private capital to enter at favorable valuations before full legalization.
California Progress: California is actively working to establish a coherent banking system; San Francisco operates as a "sanctuary city" with no local prosecution, serving as a testing ground for regulatory models.

Opioid Alternative: Anecdotal and macro data suggest cannabis serves as a primary alternative to opioids, with patients reporting relief from pain, insomnia, and anxiety without the addictive properties of pharmaceuticals.
Pediatric Applications: High-profile cases, such as Charlotte Figi (epilepsy), have driven significant public support and state-level legislative changes for pediatric epilepsy treatment using CBD.
Veterans and Athletes: The NFL Retired Players Association is exploring cannabis for pain management and PTSD among retired players; the industry is lobbying for certification and research to support adoption.
Clinical Research Gaps: There is a critical shortage of clinical trials in the U.S. due to federal restrictions; most current research is conducted in Israel or Uruguay.
Quality Control: State-mandated third-party testing ensures product safety regarding potency, pesticides, and contaminants; advanced facilities utilize in-house gas chromatography and HPLC machines.
Social Justice: Advocates highlight the need to address the "New Jim Crow" effects of the war on drugs, specifically the disproportionate impact on young African-American males and the need for decriminalization to restore economic opportunity.

Market Saturation: Panelists agree the market is years away from saturation, particularly in international export markets where production capacity lags significantly behind demand.
Investment Timing: The "Green Rush" is currently in early stages; institutional capital is restricted by federal illegality, leaving opportunities for private investors to acquire distressed assets or equity at low valuations.
Sub-Sector Opportunities: While flower remains a commodity, value is shifting toward branded end-use products (vapes, edibles, patches) and pharmaceutical-grade CBD with patent potential.
Global Commodity: The industry is expected to evolve into a global agricultural commodity similar to soy or corn, with Uruguay and the U.S. serving as primary low-cost producers.
Advocacy Strategy: Successful lobbying requires focusing on adult, medical narratives and health data rather than recreational usage; removing the stigma of "stoner" imagery is deemed essential for federal policy changes.